Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 08, 2016 08:00 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Provides Update on Tarextumab Phase 2 Programs

REDWOOD CITY, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
February 04, 2016 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
January 25, 2016 07:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Provides Update on Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial

REDWOOD CITY, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
January 22, 2016 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium

REDWOOD CITY, Calif., Jan. 22, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
January 11, 2016 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Enrolls First Patient in Phase 1b Anti-RSPO3 Trial

REDWOOD CITY, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics,...
January 08, 2016 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Announces Publication of Anti-RSPO Antibody Research in Cancer Research

REDWOOD CITY, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
January 06, 2016 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Appoints Perry Karsen to Board of Directors

REDWOOD CITY, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc., (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
January 05, 2016 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Achieves $72.5 Million in Milestone Payments From Celgene; Announces Year-End Cash Balance

$70 Million Safety and $2.5 Million Clinical Candidate Designation Milestones Achieved Enters 2016 with $227 Million in Pro-Forma Cash REDWOOD CITY, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) --...
January 04, 2016 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals CEO to Present at the 34th Annual JPMorgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
December 11, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Vantictumab Biomarker Data at the San Antonio Breast Cancer Symposium (SABCS)

REDWOOD CITY, Calif., Dec. 11, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented new data related to the development of a novel predictive biomarker for vantictumab...